Comparison of Three Methods for Early Detection of Breast Cancer

Early Phase 1CompletedNCT03954015

Mayo Clinic3 enrolled

Overview

Subjects with suspicious breast lesion (BIRADS category 4/5) who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with Contrast Enhanced Dual Energy Mammography (CEDM), Contrast Enhanced Breast MR (CEMR) and Contrast Enhanced Ultrasound (CEUS).

The co-primary endpoints are to estimate the sensitivity and specificity of CEUS relative to pathology determined diagnosis. 1. Positive predictive value of CEDM in detecting lesions seen on MR 2. Estimate the negative predictive value (TN/(TN+FN)) of CEUS as an adjunct. 3. Compare the frequency of recommendation of biopsy of MG±US vs MG±US plus CEUS as an adjunct based on BIRADS scores. 4. Comparison of background enhancement seen on CEUS with that seen on CEDM and CEMR.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Proliferative Breast Disease

Interventions

Contrast Enhanced imagingDIAGNOSTIC_TEST

Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.

LumasonDRUG

FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.

Eligibility

Sex: FEMALEMin age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Patients, greater than 30 years of age * In good general health as evidenced by medical history * BIRADS 4 or 5 suspicious breast lesions who are scheduled for breast biopsy. Exclusion Criteria: * Patients who are less than 30 years of age * Have known or suspected cardiac shunts * Have history of hypersensitive allergic reactions to any imaging contrast agents * Pregnant (a urine pregnancy test will be given at no cost to the patient) * Are nursing babies * Poor renal function * Are unwilling or unable (such as having a pacemaker) to undergo a CEMR

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

CEUS true positive diagnosis

The number of CEUS true positive diagnosis defined as suspicious enhancement/ mass corresponding to area of malignant pathology at the time of biopsy based on lesion biopsy recommendation from diagnostic mammogram.

Time frame: 1 year

CEUS false positive diagnosis

The number of CEUS false positive diagnosis defined as suspicious enhancement corresponding to area of benign pathology at the time of biopsy based on lesion biopsy recommendation from diagnostic mammogram

Time frame: 1 year

CEUS true negative diagnosis

The number of CEUS true negative diagnosis defined as no enhancement corresponding to area of malignant pathology at the time of biopsy based on lesion biopsy recommendation from diagnostic mammogram.

Time frame: 1 year

CEUS false negative diagnosis

The number of CEUS false negative diagnosis defined as no enhancement corresponding to area of benign pathology at the time of biopsy based on lesion biopsy recommendation from diagnostic mammogram.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.